MOR103: Completed Phase Ib/IIa enrollment

MorphoSys completed enrollment of 96 patients in a double-blind, placebo-controlled, European Phase Ib/IIa trial evaluating 0.3, 1.0 and 1.5 mg/kg IV MOR103. ...